Search / Trial NCT06225297

Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal

Launched by PATH · Jan 17, 2024

Trial Information

Current as of December 21, 2024

Active, not recruiting

Keywords

ClinConnect Summary

In Senegal, young children (mostly boys) may be sent to religious schools (daaras) to learn about the Koran and moral and cultural values. The students (talibés) often live and sleep in crowded conditions and as a result, insecticide-treated net (ITN) use is consistently low due to challenges faced in hanging ITNs as well as difficulty covering multiple children sleeping together. This study will consist of a two-arm cluster-randomized controlled trial to evaluate the effectiveness of an intervention package in urban daaras in Touba City, Diourbel region, Senegal.

The intervention package ...

Gender

ALL

Eligibility criteria

  • Inclusion criteria for daara:
  • Located within the catchment area of Touba Health District
  • Located within the catchment area of a health facility with an annual malaria incidence of ≥ 25 cases per 1000 population
  • Daara is registered in the health system and the Serigne daara (i.e., daara leader) can provide caregiver consent for taalibé.
  • Taalibé population between 29 to 120
  • PECAdaara model has been integrated and fully operational
  • Willingness of daara leader to participate in the study
  • Inclusion criteria for receiving DHA-PQ:
  • Age ≥ 3 months
  • Taalibé of study daara
  • Willingness to comply with study procedures
  • Provision of informed consent/assent
  • Additional inclusion criteria for receiving meganets:
  • - Sleeping in a superimposed area with ≥ 2 people
  • Exclusion Criteria for receiving DHA-PQ:
  • Age \< 3 months
  • Refusal of informed consent
  • Concomitant or recent use of antimalarials within the past two weeks
  • Known allergy or hypersensitivity to DHA-PQ
  • Confirmed diagnosis of clinical malaria
  • Currently taking anti-worm or anti-infection drugs, including cotrimoxazole (BACTRIM), mebendazole, quinolones, sulfonamides (FANSIDAR, MALOXINE), dapsone, colchicine
  • Currently taking medications that influence cardiac function or prolong the QTc interval
  • Serious or chronic illness, including known HIV infection, heart disease, or severe malnutrition (weight-for-age or mid-upper arm circumference (MUAC) \< 3 SD)
  • Pregnancy (assessed by history or urine pregnancy test)

Trial Officials

Jean Louis Ndiaye

Principal Investigator

L'université de Thiès

About Path

Path is a leading global non-profit organization dedicated to improving public health by developing and implementing innovative solutions to health challenges. With a focus on enhancing healthcare access and equity, Path collaborates with governments, NGOs, and private sector partners to design and deliver effective interventions and technologies. The organization specializes in areas such as infectious diseases, maternal and child health, and vaccine development, leveraging research and data to inform evidence-based practices. Through its commitment to advancing health systems and empowering communities, Path strives to create sustainable health improvements for populations worldwide.

Locations

Touba, , Senegal

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0